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The varicella-zoster virus 0/ZV) causes two different clinical
presentations: chickenpox and herpes zoster [1,2]. The majority
ofpeople have chickenpox in childhood. After chickenpox, the
VZV remains dormant in the sensory ganglia for the person's
entire life. The mechanism of its maintenance in the dormant
phase remains unclear, as does the cause of its reactivation [3].
After chickenpox, specific IgG antibodies remain in the serum,
but they do not prevent the reactivation ofthe virus, i.e. herpes
zoster. Cellular immunity is probably more important than
humoral immunity in the maintenance of the virus in the
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dormant phase. Diseases impairing this part of the immune
system increase the risk of herpes zoster [4]. In 10-20% of the
population, VZV is reactivated and spreads along the sensory
nerves to the skin, where it causes lesions characteristic of
herpes zoster [5].
In adults, herpes zoster most frequently appears in the
abdominal or thoracic regions, and in the elderly also as
ophthalmic herpes zoster [6]. The clinical presentation of
herpes zoster is characteristic and usually requires no laboratory
confirmation. It recurs a second time in 4% ofpatients, and only
in exceptional cases does it recur a third time [7]. Herpes zoster
most often occurs without any complications. The most fre-
quent complication is prolonged pain, which can last for several
months or even years after the disappearance of skin lesions.
Other complications are rare [4].
The incidence ofherpes zoster increases with age. According
to data from a US study, as many as 30% of patients with herpes
zoster were older than 55, even though they accounted for only
8% ofthe entire population [7]. Childhood herpes zoster is rare
and therefore ouly a small amount of data has been collected.
This paper presents our data on reported cases of herpes zoster
in childhood.
In 1996, herpes zoster was added to the list of
reportable communicable diseases in our country. The data
were collected at the Center for Communicable Diseases. In the
period from January 1996 to December 1998, 126 non-hospi-
talized cases of herpes zoster were reported in children up to
15 years of age. The physicians reporting these cases
were requested to fill out a short questionnaire and provide
additional data on these children. Additional data requested by
physicians were: date of birth, the exact date of varicella and
herpes zoster, the localization of herpes zoster, any possible
complications, whether or not the child was treated with
acyclovir and for how long, the occurrence of varicella during
pregnancy, and whether there was a congenital abnormality or
any chronic disease (how long the chronic disease was present,
and the therapy prescribed). It is presumed that most of the
diagnoses of herpes zoster were clinical. Information on
whether the case of herpes zoster was laboratory-proven was
not required.
The response rate was 68.2%, so 86 (35 boys and 51 girls)
children remained for the final analysis of the data. The reasons
for not complying with our request for more detailed informa-
tion on reported herpes zoster were not investigated.
Herpes zoster appeared throughout the year without a
characteristic seasonal peak as is observed in chickenpox.
The majority of ill children were aged between 14 and 15,
and ouly a few were younger than 4 years (Figure 1). In one
child who had herpes zoster at 14 months, it was found that the
mother had had chickenpox during pregnancy. The data on the
child's age during chickenpox were stated for 60 children, while
for six children the medical file ouly contained a note that they
Figure 1 Age of children with herpes zoster.
had chickenpox, but the exact age was not stated. Ten of the
children did not have a clinical history of chickenpox, and for a
further 10 there were no data. The interval between chickenpox
and the appearance ofherpes zoster ranged from less than 1 year
to 13 years (Fignre 2).
In the majority of children, herpes zoster was located in the
thoracic region (64 children, or 74.4%); more rarely it was
located in the cervical region (10 children, 11.6%) or lumbo-
sacral region (10 children, 11.6%), and in only two (2.4%)
children was it located in the facial region. There were no
complications, and ouly 14 (12%) children were treated with
acyclovir. The children who had herpes zoster were maiuly
healthy. Seven children were being treated for asthma (one child
with inhaled steroids, others with bronchodilators) and one for
toxoplasma panuveitis. One child had alopecia areata and
received corticosteroids, and another was treated for rhabdo-
myosarcoma.
Studies analyzing herpes zoster in childhood are extremely
rare. They maiuly describe the course of herpes zoster in
children with malignant diseases who were treated in hospital
[8,9]. Ouly two studies included children with herpes zoster
who were mainly treated in outpatient facilities [10,11]. Data on
the incidence of herpes zoster in childhood were collected in
Figure 2 Time elapsed between chickenpox and herpes zoster.
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the first study. Guess [10] found that 20 in 100000 children
under the age of 5 fall ill, and 63 in 100 000 ofpersons between
the ages of 15 and 19. Herpes zoster was significantly more
frequent in children with acute lymphocytic leukemia. Accord-
ing to the data from this study, the risk factor for childhood
herpes zoster was chickenpox before the first year of age.
Another study [11], which was conducted a few years ago,
reported an even higher incidence ofherpes zoster; it affects 160
in 100 000 persons younger than 19. Herpes zoster most
frequently appeared in the thoracic region. The course of
the disease was mainly mild, and none of the patients had
post-herpetic neuralgia. A significantly higher number of com-
plications were observed in adult patients [3].
The data we collected do not differ from those of the above-
mentioned studies. The number of patients was found to
increase with age. The interval between chickenpox and herpes
zoster was 5.6 years on average. In a study conducted on the
popnlation of Iceland, on average slightly more than 8 years
passed from chickenpox to the appearance of herpes zoster, but
adolescents with herpes zoster aged up to 19 were also included.
In all of our patients, the course of the disease was extremely
mild and there were no complications. It is therefore disputable
whether treatment with acyclovir is justified, apart from excep-
tional cases (e.g. in severely immunocompromised children). In
the children from this study as well, herpes zoster was most often
located in the thoracic area and only in one child in the
ophthalmic area. In adnlts, however, thoracic herpes zoster is
found in only half of the cases and cranial herpes zoster in over
10% of patients [5].
In children whose mothers had chickenpox during preg-
nancy, herpes zoster may appear as early as the first year oflife. In
only one of86 children did the mother have chickenpox during
pregnancy, and herpes zoster appeared very soon after the first
year of life. The immune system of the fetus is undoubtedly
immature, which, in the opinion of some, is the reason for the
early appearance of the disease [2]. The correlation between
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chickenpox before the first year of age and herpes zoster in
children was not analyzed, because the number ofchildren with
chickenpox at the age ofless than 1 year was insufficient to form
a sample.
Even though herpes zoster is a disease of the elderly, it is not
all that rare in children; however, the course of the disease is
mainly mild and without sequelae.
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Cefditoren is a new expanded-spectrum orally administered
cephalosporin currently undergoing clinical trials in the USA
[1]. Its antimicrobial spectrum includes both Gram-positive and
Gram-negative species, but it is noteworthy for its particnlar
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